Navigation Links
Clarient Reports 2009 Third Quarter; Nine Month Results
Date:11/3/2009

--- --- ----- ----- Adjusted EBITDA $(1,551) $1,387 $3,055 $2,571 ======= ====== ====== ====== (*) Adjusted for certain reclassifications between cost of services and operating expenses as a result of an income statement classification error discovered during the fourth quarter of 2008.


                                Clarient, Inc.
                     Condensed Consolidated Balance Sheets
                                (in thousands)
                                 (Unaudited)

                                           September 30,        December 31,
                                               2009                2008
                                               ----                ----

    Cash and cash equivalents                 $8,149              $1,838
    Restricted cash                            2,825                   -
    Accounts receivable, net                  24,605              20,315
    Property and equipment, net               13,686              11,911
    Other assets                               2,051               1,445
                                               -----               -----

    Total assets                             $51,316             $35,509
                                             =======             =======

    Total liabilities                        $18,136             $40,249
    Temporary equity(**)                      42,876                   -
    Stockholders' deficit                     (9,696)             (4,740)
                                              ------              ------

    Total liabilities and
     stockholders' deficit                   $51,316             $35,509
                                             =======             =======


    (**) Represents 5,263,158 shares of Series A preferred stock reclassified
    to temporary equity from
'/>"/>
SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Clarient to Present at Noble Financials 5th Annual Equity Conference on Tuesday, June 9th
2. Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
3. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
4. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
5. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
6. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
7. Jim Agnello to Resign as Clarient Chief Financial Officer
8. Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
9. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
10. Clarient to Commercialize Novel Breast Cancer Profile
11. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... GUELPH, ON , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. ... the three and six-month periods ended June 30, 2015. Biorem,s complete ... ( www.sedar.com ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per ... , 2014 , 2015 , ... 9,398 , 4,433 Gross profit , 1,656 ...
(Date:8/27/2015)... ... 27, 2015 , ... METTLER TOLEDO's web-based EasyFinder™ ... choices to a manageable shortlist of bench and floor scales and terminals. Specifying ... best with the customer’s industry and application. , Side-by-side product comparisons and ...
(Date:8/26/2015)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended June 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... our Oral Amp B program, rapidly advancing towards ... Andrew Rae , President & CEO of iCo ...
(Date:8/26/2015)... FRANCISCO , Aug. 26, 2015  Platform ... that it has received a $1.5M Phase II ... (NIH) to further develop its therapeutic agent to ... clinical need in end stage renal disease (ESRD) ... the National Institute of Diabetes and Digestive and ...
Breaking Biology Technology:BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3METTLER TOLEDO Updates Online Scale Selection Tool 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
... Michael Leist Varian , ... Introduction , ... greatly between the various chemical species in which an element occurs, ... one such example where the various species differ; the inorganic trivalent ...
... Tran T. Nham Varian Australia Pty Ltd Mulgrave, Victoria, Australia , ... Because of the low detection limit capability of ... widely used to determine trace and ultratrace levels in water samples 1 ... the ultrasonic nebulizer to handle samples with significant amounts of dissolved solids, ...
... Pond, Jason S. Wood, and August Specht Varian, Inc. , ... Alprazolam (Xanax) and Temazepam (Restoril) were ... after protein precipitation using Liquid Chromatography Electrospray Ionization Mass Spectrometry (LC/ESI/MS/MS). ... and accurately quantitate these drugs in the BSA matrix is investigated ...
Cached Biology Technology:Speciation of Arsenic by LC-ICP-MS 2Speciation of Arsenic by LC-ICP-MS 3Speciation of Arsenic by LC-ICP-MS 4Speciation of Arsenic by LC-ICP-MS 5Analysis of urine and seawater samples by ultrasonic nebulization with a high resolution ICP spectrometer 2Analysis of urine and seawater samples by ultrasonic nebulization with a high resolution ICP spectrometer 3Analysis of urine and seawater samples by ultrasonic nebulization with a high resolution ICP spectrometer 4Detection of Alprazolam and Temazepam in a Bovine Plasma Matrix Using the Varian 500-MS Ion Trap Mass Spectrometer 2Detection of Alprazolam and Temazepam in a Bovine Plasma Matrix Using the Varian 500-MS Ion Trap Mass Spectrometer 3
(Date:8/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... Alliance and the EMV Migration Forum.  ... Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. direct ... promoting adoption of smart card technology. To ...
(Date:8/18/2015)... , Aug. 18, 2015  Navitas today ... contributor to the Submission Content Management webinar ... a non-profit forum. Dedicated to the Implementation of ... neutral platform for industry, vendors, health authorities, ... and work towards a standard method of ...
(Date:8/17/2015)... , Aug. 17, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... sales campaign for Q4 2015. The new marketing campaign ... consisting of Amplitude Marketing Group ( http://amplitudemarketing.com/ ) and ... is a leader in retail driven marketing and brand ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... Shocking new research shows size isn,t always an ... that bigger is better. Michael Kasumovic, a ... Redback male spiders to determine whether the larger ones ... offspring. Surprisingly, Kasumovic found the large spiders didn,t ...
... decades, the number of adults consuming sugar-sweetened beverages ... has increased dramatically, according to a study led ... of Public Health. Researchers examined changes over the ... on nationally representative survey data, and found that ...
... --The U.S. Environmental Protection Agency and U.S. Department of ... (NCII) to learn more about the effectiveness of actions ... basin and into the northern Gulf of Mexico, says ... The report also advises how to move forward on ...
Cached Biology News:Sweetened beverage consumption increases in the US 2EPA and USDA should create new initiative to better monitor nutrients 2EPA and USDA should create new initiative to better monitor nutrients 3EPA and USDA should create new initiative to better monitor nutrients 4
6-keto Prostaglandin F1α EIA Antiserum 6-keto-PGF1alpha EIAs prostaglandins antisera enzyme immunoassays reagents 6-keto-PGF1.alpha....
... reagent has been developed for use ... reduction of nonspecific background staining due ... describe blocking peroxidase with hydrogen peroxide. ... in combination with additional novel components ...
Phospho-Btk (Tyr223) Antibody...
Rad51B...
Biology Products: